ARCHIVES

Cytogen Corp.’s Imaging Agent ProstaScint Added to NCCN Prostate Cancer Guidelines.

This article is from The Cancer Letter archive.

Vol. 26 No. 13 | March 31, 2000

Download PDF Visit The Full Archive

Related Articles

IMRT Usage and Cost Related to Geography And Medicare Reimbursement Policy, Study Finds

April 29, 2011

ODAC Recommends Approval of Evista for Breast Cancer Risk Reduction.

July 27, 2007

Early Clinical Trials Of Targeted Therapies Highlighted At AACR-NCI-EORTC Meeting

October 26, 2007

President Accepts Compromise On HEW Money Bill; Cancer Gets $523.6 Million

December 21, 1973

Lower Dose Dexamethasone Can Be Used To Treat Newly Diagnosed Myeloma

November 27, 2009

DCT Board To Consider RFA for Clinical R01 Grants At Next Meetings

January 21, 1994